LIFECELL CORP
10-Q, EX-27, 2000-11-14
COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Previous: LIFECELL CORP, 10-Q, 2000-11-14
Next: PENSKE CORP, 13F-HR, 2000-11-14



<TABLE> <S> <C>

<ARTICLE> 5
<MULTIPLIER> 1

<S>                                     <C>
<PERIOD-TYPE>                           9-MOS
<FISCAL-YEAR-END>                       DEC-31-2000
<PERIOD-START>                          JAN-01-2000
<PERIOD-END>                            DEC-30-2000
<CASH>                                     802,000
<SECURITIES>                               315,000
<RECEIVABLES>                            4,914,000
<ALLOWANCES>                               (71,000)
<INVENTORY>                              4,462,000
<CURRENT-ASSETS>                        10,736,000
<PP&E>                                  12,560,000
<DEPRECIATION>                          (2,352,000)
<TOTAL-ASSETS>                          21,629,000
<CURRENT-LIABILITIES>                   12,197,000
<BONDS>                                          0
                       14,000
                                      0
<COMMON>                                         0
<OTHER-SE>                                 862,000
<TOTAL-LIABILITY-AND-EQUITY>            21,629,000
<SALES>                                 15,744,000
<TOTAL-REVENUES>                        16,913,000
<CGS>                                    4,793,000
<TOTAL-COSTS>                           21,430,000
<OTHER-EXPENSES>                                 0
<LOSS-PROVISION>                                 0
<INTEREST-EXPENSE>                         579,000
<INCOME-PRETAX>                         (4,954,000)
<INCOME-TAX>                                     0
<INCOME-CONTINUING>                     (4,954,000)
<DISCONTINUED>                                   0
<EXTRAORDINARY>                                  0
<CHANGES>                                        0
<NET-INCOME>                            (4,954,000)
<EPS-BASIC>                                (.390)
<EPS-DILUTED>                                (.390)


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission